Nasus Pharma LTD 6-K Filing
Ticker: NSRX · Form: 6-K · Filed: Dec 22, 2025 · CIK: 2029039
| Field | Detail |
|---|---|
| Company | Nasus Pharma LTD (NSRX) |
| Form Type | 6-K |
| Filed Date | Dec 22, 2025 |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Nasus Pharma LTD (ticker: NSRX) to the SEC on Dec 22, 2025.
How long is this filing?
Nasus Pharma LTD's 6-K filing is 1 pages with approximately 196 words. Estimated reading time is 1 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 196 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2025-12-22 08:15:13
Filing Documents
- form6-k.htm (6-K) — 16KB
- ex99-1.htm (EX-99.1) — 24KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-25-028664.txt ( ) — 45KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2025 Commission File Number: 001-42796 Nasus Pharma Ltd. Yigal Alon 65 Tel Aviv, Israel 6744317 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS On December 22, 2025, Nasus Pharma Ltd. (the “Company”) issued a press release titled “Nasus Pharma CEO Issues 2025 Letter to Shareholders,” a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K. EXHIBIT INDEX Exhibit No. Description 99.1 Press Release issued on December 22, 2025 by Nasus Pharma Ltd. titled “Nasus Pharma CEO Issues 2025 Letter to Shareholders” SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NASUS PHARMA LTD. Date: December 22, 2025 By: /s/ Dan Teleman Name: Dan Teleman Title: Chief Executive Officer